GeneVentiv Therapeutics
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Raleigh, North Carolina, United StatesWebsite
www.geneventiv.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About GeneVentiv Therapeutics
Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with their missing clotting factor. Read MoreExplore more
GeneVentiv Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GeneVentiv Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once GeneVentiv Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
GeneVentiv Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if GeneVentiv Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on GeneVentiv Therapeutics recently announced quarterly report
Check if GeneVentiv Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at GeneVentiv Therapeutics
Product Launch: Get notified when GeneVentiv Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if GeneVentiv Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined GeneVentiv Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to GeneVentiv Therapeutics
Compare insights from companies similar to GeneVentiv Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GeneVentiv Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GeneVentiv Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GeneVentiv Therapeutics.
GeneVentiv Therapeutics Tech Stack
A closer look at the technologies used by GeneVentiv Therapeutics
See more technologies
GeneVentiv Therapeutics News & Media
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ -- GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR) grant for approximately $2,500,000...ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
ReciBioPharm (https://www.recipharm.com/recibiopharm), the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics (https://www.geneventiv.com/), a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors. On average 30 percent of people with haemophilia A and about 5 percent of peopl
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GeneVentiv Therapeutics
Sign Up For FreeTo access detailed company insights
Patients with inhibitors are unable to respond to current therapies and gene therapies in development due to neutralizing antibodies (inhibitors) formed by the body in response to treatment with their missing clotting factor. Read More... Read More
